Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential Cheng J; Kamiya K; Kodama ICardiovasc Drug Rev 2001[Sum]; 19 (2): 152-71Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection.|Adrenergic alpha-Antagonists/pharmacology/therapeutic use[MESH]|Adrenergic beta-Antagonists/pharmacology/therapeutic use[MESH]|Animals[MESH]|Antihypertensive Agents/pharmacology/therapeutic use[MESH]|Antioxidants/pharmacology/therapeutic use[MESH]|Blood Glucose/metabolism[MESH]|Carbazoles/pharmacokinetics/*pharmacology/*therapeutic use[MESH]|Cardiovascular Agents/pharmacokinetics/*pharmacology/*therapeutic use[MESH]|Cardiovascular System/drug effects/physiopathology[MESH]|Carvedilol[MESH]|Heart Conduction System/drug effects[MESH]|Heart Failure/drug therapy[MESH]|Humans[MESH]|Hypertension/drug therapy[MESH]|Lipids/blood[MESH]|Myocardial Ischemia/drug therapy[MESH]|Neurotransmitter Agents/physiology[MESH]|Propanolamines/pharmacokinetics/*pharmacology/*therapeutic use[MESH] |